[go: up one dir, main page]

FR3060389B1 - Comprime enrobe comprenant de l'ulipristal acetate ou un de ses metabolites - Google Patents

Comprime enrobe comprenant de l'ulipristal acetate ou un de ses metabolites Download PDF

Info

Publication number
FR3060389B1
FR3060389B1 FR1662926A FR1662926A FR3060389B1 FR 3060389 B1 FR3060389 B1 FR 3060389B1 FR 1662926 A FR1662926 A FR 1662926A FR 1662926 A FR1662926 A FR 1662926A FR 3060389 B1 FR3060389 B1 FR 3060389B1
Authority
FR
France
Prior art keywords
enrobe
metabolites
ulipristal acetate
tablet
ulipristal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1662926A
Other languages
English (en)
Other versions
FR3060389A1 (fr
Inventor
Christine SEGUIN
Suzanne Tran-Fernandes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratoire HRA Pharma SAS
Original Assignee
Laboratoire HRA Pharma SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoire HRA Pharma SAS filed Critical Laboratoire HRA Pharma SAS
Priority to FR1662926A priority Critical patent/FR3060389B1/fr
Priority to PCT/FR2017/053735 priority patent/WO2018115743A1/fr
Publication of FR3060389A1 publication Critical patent/FR3060389A1/fr
Application granted granted Critical
Publication of FR3060389B1 publication Critical patent/FR3060389B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)

Abstract

La présente invention a pour objet un comprimé enrobé comprenant de l'ulipristal acétate ou un de ses métabolites en tant que principe actif et les utilisations contraceptives et thérapeutiques dudit comprimé.
FR1662926A 2016-12-20 2016-12-20 Comprime enrobe comprenant de l'ulipristal acetate ou un de ses metabolites Active FR3060389B1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
FR1662926A FR3060389B1 (fr) 2016-12-20 2016-12-20 Comprime enrobe comprenant de l'ulipristal acetate ou un de ses metabolites
PCT/FR2017/053735 WO2018115743A1 (fr) 2016-12-20 2017-12-20 Comprime enrobe comprenant de l'ulipristal acétate ou un de ses métabolites

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1662926A FR3060389B1 (fr) 2016-12-20 2016-12-20 Comprime enrobe comprenant de l'ulipristal acetate ou un de ses metabolites
FR1662926 2016-12-20

Publications (2)

Publication Number Publication Date
FR3060389A1 FR3060389A1 (fr) 2018-06-22
FR3060389B1 true FR3060389B1 (fr) 2019-05-31

Family

ID=58501547

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1662926A Active FR3060389B1 (fr) 2016-12-20 2016-12-20 Comprime enrobe comprenant de l'ulipristal acetate ou un de ses metabolites

Country Status (2)

Country Link
FR (1) FR3060389B1 (fr)
WO (1) WO2018115743A1 (fr)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4954490A (en) 1988-06-23 1990-09-04 Research Triangle Institute 11 β-substituted progesterone analogs
ES2212912B1 (es) 2003-01-22 2005-10-01 Crystal Pharma, S.A. Procedimiento para la obtencion de 17alfa-acetoxi-11beta-(4-n,n-dimetilaminofenil)-19-norpregna-4,9-dien-3,20-diona.
US8512745B2 (en) 2008-12-08 2013-08-20 Laboratoire Hra Pharma Ulipristal acetate tablets
US9616073B2 (en) 2009-04-14 2017-04-11 Laboratoire Hra-Pharma Method for on-demand contraception
CN102727457B (zh) * 2011-04-08 2014-05-28 华润紫竹药业有限公司 稳定的醋酸优力司特制剂
FR2997628B1 (fr) * 2012-11-08 2015-01-16 Hra Pharma Lab Produit de co-micronisation comprenant un modulateur selectif des recepteurs a la progesterone
FR2997627B1 (fr) 2012-11-08 2015-01-16 Hra Pharma Lab Produit de co-micronisation comprenant de l'ulipristal acetate
FR2999081B1 (fr) 2012-12-06 2015-02-27 Hra Pharma Lab Dispersion solide d'un modulateur selectif du recepteur a la progesterone

Also Published As

Publication number Publication date
WO2018115743A1 (fr) 2018-06-28
FR3060389A1 (fr) 2018-06-22

Similar Documents

Publication Publication Date Title
MA49043A (fr) Formulation stable d'anticorps
MX2020006460A (es) Compuestos de anillo 5,5 fusionado sustituido con diarilo como inhibidores de c5ar.
MA53356B1 (fr) Formulations sous-cutanées d'anticorps anti-cd38 et leurs utilisations
WO2021021837A3 (fr) Formulations d'anticorps anti-pvrig et leurs utilisations
WO2018075692A3 (fr) Constructions d'anticorps
EP4516355A3 (fr) Formulations de cannabinoïdes stables
BR112015023391A2 (pt) formulações compreendendo conjugado droga-anticorpo anti-egfr
MA38960A1 (fr) Formulations d'anticorps anti-pdl1
EP3643723A4 (fr) Nouveau peptide et composition pharmaceutique pour le traitement de maladies oculaires comprenant ledit nouveau peptide en tant que principe actif
FR3021970B1 (fr) Anticorps dirige contre la galectine 9 et inhibiteur de l'activite suppressive des lymphocytes t regulateurs
MX2023001963A (es) Composiciones farmaceuticas hipertonicas que contienen un agente quimioprotector antiplatino.
AR098168A1 (es) Formulación estable de insulina glulisina
EP4559485A3 (fr) Formulation d'anticorps liquide
EP3695830A4 (fr) Utilisation d'une composition comprenant des exosomes dérivés de cellules souches en tant que principe actif pour le renforcement et l'amélioration fonctionnelle de la barrière cutanée
EP3672587A4 (fr) Compositions pharmaceutiques destinées au traitement d'affections ophtalmiques
MA50406B1 (fr) Inhibiteurs pyrazole de magl
JOP20210229A1 (ar) صيغة جسم مضاد علاجي
MA53466A (fr) Formulation stable d'anticorps anti-osmr
MA43876A (fr) Compositions pharmaceutiques et leur utilisations contre les maladies de surcharge lysosomale
MX392163B (es) Moduladores de ror gamma.
MX2018000021A (es) Composiciones multifasicas.
EP3610869A4 (fr) Composition contenant du sarpogrélate en tant que principe actif, pour la prévention ou le traitement de la perte auditive neurosensorielle
EP3701970A4 (fr) Agent de stimulation de l'immunité, agent anti-cancéreux immuno-thérapeutique, et agent d'atténuation d'effets indésirables de la thérapie anticancéreuse contenant un complexe anthocyanine-fucoïdane en tant que principe actif
EP3668991A4 (fr) Nanosupports pour l'administration de principes actifs
EA201990550A1 (ru) Офтальмологический препарат, включающий азоловое соединение

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20180622

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7

PLFP Fee payment

Year of fee payment: 8

PLFP Fee payment

Year of fee payment: 9

PLFP Fee payment

Year of fee payment: 10